In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Financings: Recent Growth, Future Opportunities

Executive Summary

In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.

Related Content

Philips Homes In on Respironics: Fills Gaps in Care Continuum
Paracor: Can a Mechanical Device Treat Heart Failure?
Globus Prepared for Trek with $110m from Clarus-led Group
CardioNet Turns to Hedge Funds
InnerPulse: Bringing the Interventional Revolution to CRM
EndoGastric Solutions: Re-Inventing GERD Therapy
Kyphon's Move Into the Mainstream
Volcano Steps Up in Vulnerable Plaque By Buying Jomed's IVUS Business
Lungs Expand Device Markets
The Unstable State of Plaque Detection


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts